Novo Nordisk entered an agreement with Vivani Medical to evaluate the NPM-139 semaglutide implant. The collaboration utilizes Vivani’s NanoPortal technology for chronic weight management.
Vivani is preparing a first-in-human Phase 1 study for the subdermal device. The trial will compare the implant’s safety and pharmacokinetics to injected Wegovy.
CEO Adam Mendelsohn stated the deal validates the market potential of their GLP-1 technology. The partnership supports Novo Nordisk’s strategy to diversify delivery systems for blockbuster therapies.